Tempalgin tablets, No. 20

• Moderate or mild pain syndrome (including headache, migraine, toothache, neuralgia, radicular syndrome, myalgia, arthralgia, algomenorrhea), especially in patients with increased nervous excitability;

• mild pain of visceral origin (including renal, hepatic, intestinal colic) in combination with antispasmodic therapy;

• pain syndrome after surgical and diagnostic interventions (as an adjuvant);

• an increase in body temperature with colds and other infectious and inflammatory diseases.

Inside, after meals with water.

The dose depends on the severity of pain and individual sensitivity to the drug.

Adults: the usual dose is 1 table. 1-3 times a day. The maximum single dose should not exceed 1 table. The maximum daily dose is 4 tablets.

For dental procedures: 1 table. 30 minutes before the intervention.

Children over 15 years old: 1 tab. in a day. The maximum daily dose is 2 tablets.

Special patient groups

Patients over 65 years of age. No dose reduction is usually required. In patients with age-related impairment of kidney and liver function, treatment with TempalginЃ should be short-lived. The maximum daily dose is 2 tablets.

Liver dysfunction. In patients with impaired liver function, an increase in T1 / 2 of metamizole sodium metabolites is possible. In patients with moderate or severe liver damage, treatment with 1/2 of the recommended dose for adults is recommended (maximum daily dose - 2 tablets).

Impaired renal function. Metamizole sodium and its metabolites are excreted by the kidneys. In patients with impaired renal function, treatment with TempalginЃ should be carried out using 1/2 the recommended dose for adults (the maximum daily dose is 2 tablets).

Duration of treatment

Treatment with TempalginЃ should not last more than 3-5 days. Its use for a longer period of time or in higher doses is possible only after consulting a doctor.

Film-coated tablets

1 tab.

active substances:

metamizole sodium monohydrate 500 mg

triacetonamine-4-toluenesulfonate 20 mg

excipients: wheat starch - 95 mg; MCC - 75 mg; povidone K25 - 45 mg; talc - 15 mg; magnesium stearate - 10 mg film shell: Opadry II green 85 F 21526 - 23 mg: partially hydrolyzed polyvinyl alcohol - 9.2 mg; macrogol 3350 - 4.646 mg; talc - 3.404 mg; titanium dioxide (E171) - 4.37 mg; quinoline yellow (E104) aluminum varnish - 1.035 mg; brilliant blue (E133) FCF aluminum varnish - 0.345 mg

• Severe liver failure;

• severe renal failure;

• chronic heart failure;

• arterial hypotension (decrease in systolic blood pressure below 100 mm Hg);

• oppression of hematopoiesis (granulocytopenia, leukopenia, agranulocytosis, cytostatic or infectious neutropenia);

• deficiency of glucose-6-phosphate dehydrogenase;

• aspirin asthma;

• pregnancy;

• lactation period (breastfeeding);

• children's age (up to 14 years old);

• hypersensitivity to metamizole sodium, pyrazolone derivatives or triacetonamine-4-toluenesulfonate.

• It is prescribed with caution for kidney diseases (pyelonephritis, glomerulonephritis, including a history), moderate hepatic / renal failure, with bronchial asthma, a predisposition to the development of arterial hypotension, with prolonged alcohol abuse.

pharmachologic effect

Combined analgesic-antipyretic. It has analgesic, antipyretic, mild anti-inflammatory and sedative effects. The drug contains the non-opioid analgesic metamizole sodium and the anxiolytic (tranquilizer) tempidone.

Side effect

From the digestive system: rarely - a burning sensation in the epigastric region, dry mouth, cholestasis, jaundice, increased activity of hepatic transaminases, hyperbilirubinemia.

From the side of the central nervous system: headache, dizziness; in some cases - hallucinations.

From the side of the cardiovascular system: decrease or increase in blood pressure, tachycardia, cyanosis.

From the hematopoietic system: agranulocytosis, leukopenia, thrombocytopenia.

From the urinary system: when used in high doses - renal dysfunction (oliguria, anuria, proteinuria, interstitial nephritis); urine staining red.

Allergic reactions: skin rash, itching, urticaria (including on the conjunctiva and on the mucous membranes of the nasopharynx), Quincke's edema, exudative erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospasm, anaphylactic shock.

Application during pregnancy and lactation

The drug is contraindicated for use during pregnancy. Do not use the drug during lactation, because both components are excreted in breast milk.

Application for violations of liver function

Contraindicated in severe liver dysfunction.

Application for impaired renal function

Contraindicated in severe renal impairment.

special instructions

X-ray contrast agents, colloidal blood substitutes and penicillin should not be prescribed when using metamizole sodium.

You should not drink alcohol while taking the drug.

The use of the drug in patients receiving cytostatics should be carried out only under the supervision of a physician.

Against the background of the use of metamizole sodium, the development of agranulocytosis is possible, and therefore, if an unclear genesis of a rise in temperature, chills, sore throat, difficulty swallowing, stomatitis is detected, as well as with the development of vaginitis or proctitis, it is necessary to cancel the drug.

With prolonged (more than 7 days) administration of the drug, it is necessary to monitor the blood picture and the functional state of the liver.

It is unacceptable to use Tempalgin to relieve acute abdominal pain (until the cause is clarified).

Influence on the ability to drive vehicles and mechanisms

In connection with the anxiolytic effect of the drug during the period of taking Tempalgin, one should refrain from engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Overdose

Symptoms: nausea, vomiting, epigastric pain, oliguria, tachycardia, decreased blood pressure, shortness of breath, tinnitus, drowsiness, impaired consciousness, convulsions.

Treatment: gastric lavage, the appointment of saline laxatives and activated charcoal; in severe cases - hemodialysis, forced diuresis, symptomatic therapy, with the development of convulsive syndrome - intravenous diazepam and fast-acting barbiturates.

Drug interactions

Tempalgin enhances the effects of ethanol.

The simultaneous use of Tempalgin with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

Sedatives and tranquilizers enhance the analgesic effect of the drug.

With the simultaneous use of thiamazole and cytostatics increase the risk of developing leukopenia.

With the simultaneous use of metamizole sodium with cyclosporine, the concentration of the latter in the blood plasma decreases.

Metamizole sodium, displacing oral hypoglycemic drugs, indirect anticoagulants, GCS and indomethacin from the connection with protein, increases their effect.

With the simultaneous use of barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole sodium.

The simultaneous use of metamizole sodium with other non-opioid analgesics, tricyclic antidepressants, oral contraceptives, allopurinol can lead to mutual enhancement of toxic effects.

Codeine, blockers of histamine H2-receptors and propranolol slow down the excretion of metamizole sodium and enhance its effect.